Drawing for ALLO CHASSIS

USPTO serial 79425095

ALLO CHASSIS

Reviewed by CopyMark Law Group

Reg. 8172902Status 700Registered
Filing date
Status date
Registration date
Mar 17, 2026
Examiner
EISNACH, MICHAEL PATRICK
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ALLO CHASSIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
001Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom, for research or scientific purposes; cell cultures, cell culture systems and cryopreserved genetically modified iPS cells for scientific and industrial research purposes; cell cultures, and cryopreserved cells iPS cells other than for medical or veterinary use; Biological preparations for use in cell cultures, other than for medical or veterinary purposes, namely, cell culture agents for use in the biotechnology industry and cell material for use in combination with human cells, particularly genetically modified iPS or differentiated stem cellsACTIVE
005Modified cells, in particular genetically modified iPS (induced pluripotent stem) cells or differentiated cells derived therefrom, for medical or veterinary use; cell cultures and cell culture systems, and cryopreserved pluripotent stem cells for medical or veterinary use; genetically modified iPS (induced pluripotent stem) cells for use in generating other cells for therapeutic purposes; cell cultures and cell culture systems, and cryopreserved genetically modified pluripotent stem cells for sub cultivation of cells.ACTIVE
040Custom manufacturing of iPS derived cells, and iPS derived cell therapy and manufacturing processes for others, namely, manufacturing of the foregoing cells in GMP-based facilities; custom manufacture of therapeutic cells, medicines, cell therapies and gene edited cell therapies for others, namely, manufacturing in GMP-based facilities; custom manufacture of cellular therapies, namely, manufacturing in GMP-based facilities; manufacturing of cell lines being modified cells with specific genetic edits for use in generating other cellsACTIVE
042Research and testing of cell-based products, in particular therapeutic products; research, optimization and testing of cell production processes; laboratory research in the field of biotechnology using genetically modified iPS (induced pluripotent stem) cells and differentiated cells derived therefrom; Scientific research, design and development of scientific cell culture, cell therapy and gene edited cell therapy; Scientific research, design and development of cell culture, cell therapy or gene edited cell therapy, manufacturing systems and manufacturing processes for others; platform as a service (PAAS) services featuring computer software platforms for custom manufacturing of cell-based products, in the field of cell therapy, and cell therapy development; providing temporary use of online non-downloadable computer software platform for the management of manufacturing of cell-based therapies, namely, the associated technology, processes, and data analytics capabilities for process optimization and quality controlACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 28, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB
Aug 27, 2026FIMPFINAL DISPOSITION PROCESSED
Jun 17, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 17, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 17, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 27, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 27, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 21, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 5, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Dec 30, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Dec 30, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 30, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 22, 2025RFNTREFUSAL PROCESSED BY IB
Nov 5, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 5, 2025RFRRREFUSAL PROCESSED BY MPU
Sep 17, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 16, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 3, 2025DOCKASSIGNED TO EXAMINER
Jun 6, 2025MAFRAPPLICATION FILING RECEIPT MAILED
Jun 6, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 5, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance